Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

61 study records (showing up to 30 per record type)

• Registered trial NCT05906498 Phase 3 Not completed: Recruiting
  Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris
  Condition or outcome area: Psoriasis Vulgaris
  2022-12-01 · Subject: Vitamin E; T1539_SIGMA; NSC 82623; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; (+-)-alpha-Tocopherol; BRN 0094012; 5,7,8-Trimethyltocol; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; 6-Chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-; T3634_SIGMA · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT06106230 Completed (results not assessed here)
  Bee Venom Phonophoresis on Mild to Moderate Localized Plaque Psoriasis on Knee Joint
  Condition or outcome area: Plaque Psoriasis
  2024-01-01 · Subject: Feng Du; 蜂毒; Apisin; Veneu Apis · open the herb record · ClinicalTrials.gov
• Registered trial NCT05442190 Phase 2 Not completed: Recruiting
  Topical SGX302 for Mild-to-Moderate Psoriasis
  Condition or outcome area: Psoriasis|Plaque Psoriasis|Psoriasis Vulgaris
  2022-12-14 · Subject: Hypericin; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; (component of) Hypericum spp (st. John's wort); Cyclosan; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra]perylene-7,14-dione P-conformer; NSC 407313; Hypericin & Visible light; NCGC00162454-01; Cyclo werrol; NCI60_006799 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT00006276 Phase 2 Completed (results not assessed here)
  Micellar Paclitaxel to Treat Severe Psoriasis
  Condition or outcome area: Psoriasis
  2000-09 · Subject: Taxol; Paclitaxel · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01321164 Phase 3 Completed (results not assessed here)
  Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis
  Condition or outcome area: Plaque Psoriasis
  2011-04 · Subject: Fumaric Acid; 2-Butenoic acid; formic acid; but-2-enoic acid; methanoic acid; A802157; fumaricacid; 2-butenoic acid · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02772601 Phase 1 Completed (results not assessed here)
  This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
  Condition or outcome area: Psoriasis
  2016-09-15 · Subject: Coumarins; Warfarin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02772601 Phase 1 Completed (results not assessed here)
  This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
  Condition or outcome area: Psoriasis
  2016-09-15 · Subject: Caffeine; NCGC00015208-02; DHCplus; KBio2_001781; W222402_ALDRICH; NINDS_000730; EINECS 200-362-1; Spectrum5_000423; BSPBio_001921; KBio1_000730 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02622386 Phase 2 Completed (results not assessed here)
  The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis
  Condition or outcome area: Psoriasis
  2016-08-11 · Subject: Vitamin- G; Riboflavin; riboflavine; vitamin b2; R0508_SIAL; pentitol, 1-deoxy-1-(3,4-dihydro-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10(2H)-yl)-; 47861_SUPELCO; Vitamin- B2; InChI=1/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s; RIBOFLAVINE (VITAMIN B2) · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT00350116 Phase 3 Completed (results not assessed here)
  Topical Vitamin B12 in Chronic Plaque Psoriasis
  Condition or outcome area: Chronic Plaque Psoriasis
  2001-01 · Subject: Vitamin B12; Cyanocobalamin;Cyanocob(III)alamin · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01763424 Phase 2 / Phase 3 Completed (results not assessed here)
  Nicotinamide in the Treatment of Psoriasis
  Condition or outcome area: Psoriasis
  2011-07 · Subject: NCA; Nicotinamide; Vitamin PP; niacinamide; Aminicotin; Nicotinsaureamid; 123574-63-0; Amid kyseliny nikotinove [Czech]; Niavit PP; Nicotinamide (JP15/INN) · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01007591 Phase 3 Completed (results not assessed here)
  A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
  Condition or outcome area: Psoriasis Vulgaris
  2009-10 · Subject: 4-Pregnene-17Α,20Β,21-Triol-3,11-Dione; Hydrocortisone · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT00704262 Phase 2 Completed (results not assessed here)
  Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds
  Condition or outcome area: Psoriasis Vulgaris
  2008-05 · Subject: 4-Pregnene-17Α,20Β,21-Triol-3,11-Dione; Hydrocortisone · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT00691002 Phase 3 Completed (results not assessed here)
  Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
  Condition or outcome area: Psoriasis Vulgaris
  2008-05 · Subject: 4-Pregnene-17Α,20Β,21-Triol-3,11-Dione; Hydrocortisone · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT00640822 Phase 3 Completed (results not assessed here)
  Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds
  Condition or outcome area: Psoriasis Vulgaris
  2008-02 · Subject: 4-Pregnene-17Α,20Β,21-Triol-3,11-Dione; Hydrocortisone · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01914627 Phase 2 Completed (results not assessed here)
  Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis
  Condition or outcome area: Scalp Psoriasis
  2013-08 · Subject: 2-Hydroxybenzoic Acid; Salicylic acid · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05431959 Not completed: Unknown
  Evaluation of the Effect of Sulphur Mineral, Thermal Water on Skin Microbiome in Plaque Psoriasis, a Pilot Study
  Condition or outcome area: Plaque Psoriasis
  2021-07-25 · Subject: Liu Huang; 硫黄; Sulfur; Sulphur;Sulfur · open the herb record · ClinicalTrials.gov
• Systematic review registration CRD42023441886 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of vitamin D supplementation on patients with psoriasis: a systematic review and meta-analysis
  Condition or outcome area: Study patients were diagnosed with psoriasis.
  2023-07-14 · Subject: Vitamin d; 24,25-Dihydroxyvitamin D; (3R,6R)-6-[(1R,3aS,7aR)-4-[2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; (6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; 24,25-dihydroxyvitamin D3; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin; CHEBI:89324; Q27161510; (3b,5Z,7E)-9,10-Secocholesta-5, · open the ingredient record
• Systematic review registration CRD42021227204 Registered protocol, no results here: Review Ongoing
  Effectiveness and safety of Oral Chinese Patent Medicine combined with Conventional Western Medicine in the treatment of psoriasis vulgaris：A protocol for systematic review and Bayesian network meta-analysis
  Condition or outcome area: Psoriasis is a chronic inflammatory skin disease that affects 2–3% of the global population。Psoriasis vulgaris is the most common disease type，affects 80% to 90% of psoriasis patients。This disease results in a serious burden on affected patients as well as their families。
  2021-01-19 · Subject: Xiaoyin Jiaonang; 消银胶囊; Xiao Yin Capsule; Xiaoyin Capsule · open the formula record
• Systematic review registration CRD42021227204 Registered protocol, no results here: Review Ongoing
  Effectiveness and safety of Oral Chinese Patent Medicine combined with Conventional Western Medicine in the treatment of psoriasis vulgaris：A protocol for systematic review and Bayesian network meta-analysis
  Condition or outcome area: Psoriasis is a chronic inflammatory skin disease that affects 2–3% of the global population。Psoriasis vulgaris is the most common disease type，affects 80% to 90% of psoriasis patients。This disease results in a serious burden on affected patients as well as their families。
  2021-01-19 · Subject: Run Zao Zhi Yang Jiao Nang; 润燥止痒胶囊; Run Zao Zhi Yang Capsule · open the formula record
• Systematic review registration CRD42021227204 Registered protocol, no results here: Review Ongoing
  Effectiveness and safety of Oral Chinese Patent Medicine combined with Conventional Western Medicine in the treatment of psoriasis vulgaris：A protocol for systematic review and Bayesian network meta-analysis
  Condition or outcome area: Psoriasis is a chronic inflammatory skin disease that affects 2–3% of the global population。Psoriasis vulgaris is the most common disease type，affects 80% to 90% of psoriasis patients。This disease results in a serious burden on affected patients as well as their families。
  2021-01-19 · Subject: Ke Yin Wan; 克银丸; Ke Yin Pill · open the formula record
• Systematic review registration CRD42021227204 Registered protocol, no results here: Review Ongoing
  Effectiveness and safety of Oral Chinese Patent Medicine combined with Conventional Western Medicine in the treatment of psoriasis vulgaris：A protocol for systematic review and Bayesian network meta-analysis
  Condition or outcome area: Psoriasis is a chronic inflammatory skin disease that affects 2–3% of the global population。Psoriasis vulgaris is the most common disease type，affects 80% to 90% of psoriasis patients。This disease results in a serious burden on affected patients as well as their families。
  2021-01-19 · Subject: Fu Fang Qing Dai Wan; 复方青黛丸; Compound Qing Dai Pill; Fufang Qingdai Pill · open the formula record
• Systematic review registration CRD42020158687 Registered protocol, no results here: Review Ongoing
  Chinese herbal formula (Dang gui yin zi) for psoriasis vulgaris:a systematic review and meta-analysis of randomized controlled trials.
  Condition or outcome area: Psoriasis vulgaris
  2020-04-28 · Subject: Dang Gui Yin Zi; 当归饮子; Dang Gui Decotion; Danggui Decotion · open the formula record
• Systematic review registration CRD42022309931 Registered protocol, no results here: Review Ongoing
  Effect of vitamin C on inflammatory markers in chronic inflammatory diseases: a systematic review and meta-analysis
  Condition or outcome area: We will evaluate the effects of vitamin C on inflammatory markers (CRP, hsCRP, C3, IL-1, IL-6, IL-8, IL-12, IL-17, TNF etc.) in patients with a wide range of chronic inflammatory diseases. This chronic inflammatory diseases includes chronic inflammatory disease or psoriasis or inflammatory bowel disease or ulcerative colitis or crohn’s disease or lupus or sjogren or rheumatoid arthritis or metabolic syndrome or obesity or diabetes mellitus or cardiovascular disease or stroke or myocardial infarc
  2022-04-13 · Subject: Vitamin c; Ascorbic Acid; l-ascorbic acid; ascorbic acid; 50-81-7; L-ascorbate; Ascoltin; ascorbate; Ascorbicap; Cevitamic acid · open the ingredient record
• Systematic review registration CRD42018090140 Registered protocol, no results here: Review Completed published
  Serum homocysteine, folate and vitamin B12 levels in patients with psoriasis: a systematic review and meta-analysis
  Condition or outcome area: Patients with psoriasis and psoriatic arthritis.
  2018-03-07 · Subject: Vitamin b12; vitamin B12; cyanocobalamin; 68-19-9; Cyanocob(III)alamin; DTXCID5024346; MFCD00151092; Cobalamin (1+); Cyanocobalamin;Cyanocob(III)alamin; CAS-68-19-9 · open the ingredient record
• Systematic review registration CRD42020207143 Registered protocol, no results here: Review Ongoing
  Vitamin E levels and skin diseases: systematic review and meta-analysis
  Condition or outcome area: Skin diseases are one of the most common human diseases around the world with a high contribution to the global burden of disease (1.79%), including vitiligo, psoriasis, alopecia areata, acne, pityriasis, chloasma, eczema, cheilitis, dermatitis and so on.The symptoms of chronic skin diseases are often accompanied by itching, pain and skin damage. Reduction in quality of life is associated with these long-term symptoms that are difficult to cure, and even lead to depression. The pathophysiology o
  2020-10-01 · Subject: Vitamin e; Alpha-Tocopherol; alpha-Tocopherol; 59-02-9; D-alpha-Tocopherol; 5,7,8-Trimethyltocol; (+)-alpha-Tocopherol; 2074-53-5; alpha Tocopherol; Phytogermine · open the ingredient record
• Systematic review registration CRD42022385248 Registered protocol, no results here: Review Ongoing
  The efficacy and safety of indigo naturalis in the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials
  Condition or outcome area: Psoriasis is a chronic inflammatory disease caused by genetic and environmental factors, with a long course of disease and easy recurrence, which seriously affects the physical and mental health and quality of life of patients. At present, the treatment of psoriasis mainly includes drug therapy, physical therapy, biological therapy and psychotherapy, but the therapeutic effect is not good and easy to relapse. In recent years, the application of traditional Chinese medicine in the treatment of ps
  2022-12-30 · Subject: Indigo; 482-89-3; Indigotin; Indigo Blue; Vat blue 1; Cystoceva; Diindogen; Vulcafix Blue R; Indigo Pure BASF; Indigo Ciba · open the ingredient record
• Systematic review registration CRD42022336713 Registered protocol, no results here: Review Ongoing
  The efficacy and safety of indigo naturalis and compound indigo naturalis for the treatment of psoriasis to promote its clinical application.
  Condition or outcome area: Psoriasis; Indigo naturalis and compound indigo naturalis in the treatment of Psoriasis
  2022-06-13 · Subject: Indigo; 482-89-3; Indigotin; Indigo Blue; Vat blue 1; Cystoceva; Diindogen; Vulcafix Blue R; Indigo Pure BASF; Indigo Ciba · open the ingredient record
• Systematic review registration CRD42022326526 Registered protocol, no results here: Review Ongoing
  Topical indigo naturalis preparation in the treatment of psoriasis: a systematic review and meta-analysis
  Condition or outcome area: Psoriasis is an inflammatory and relapsing skin disease that affects at least 1.25 billion people's physical and mental health all around the world. Nowadays, there is an increasing risk of psoriasis comorbidites such as psoriatic arthritis and cardiometabolic diseases, which has attached great importance to psoriasis treatment. At present, the treatment of psoriasis is mainly biologics and oral systematic therapies such as methotrexate, which are reported to increase adverse events in the long
  2022-06-03 · Subject: Indigo; 482-89-3; Indigotin; Indigo Blue; Vat blue 1; Cystoceva; Diindogen; Vulcafix Blue R; Indigo Pure BASF; Indigo Ciba · open the ingredient record
• Systematic review registration CRD42015027763 Registered protocol, no results here: Review Completed published
  Compound glycyrrhizin combined with conventional therapy for psoriasis vulgaris: a systematic review of randomized controlled trials
  Condition or outcome area: Psoriasis vulgaris
  2015-10-31 · Subject: Glycyrrhizin; Glycyrrhizic acid; 1405-86-3; Glycyron; Glycyrrhizinic acid; Glycyrrhetinic acid glycoside; potenlini; Glizigen; glycyrrhizate; glyzyrrhizin · open the ingredient record
• Systematic review registration CRD42023392882 Registered protocol, no results here: Review Ongoing
  Effect of compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trial
  Condition or outcome area: Psoriasis Vulgaris (PV).
  2023-01-29 · Subject: Glycyrrhizin; Glycyrrhizic acid; 1405-86-3; Glycyron; Glycyrrhizinic acid; Glycyrrhetinic acid glycoside; potenlini; Glizigen; glycyrrhizate; glyzyrrhizin · open the ingredient record
• Systematic review registration CRD42020172575 Registered protocol, no results here: status not recorded
  Protocol for a systematic review without meta-analysis of the safety of sphingosine 1 phosphate modulators in inflammatory bowel disease and other immune-mediated diseases
  Condition or outcome area: Inflammatory bowel disease (Crohn's disease and ulcerative colitis), multiple sclerosis and chronic psoriasis
  Subject: Cerebroside; Sphingosine; sphingosine; D-erythro-Sphingosine; 123-78-4; D-Sphingosine; 4-Sphingenine; Sphing-4-enine; Sphingenine; 4-trans-Sphingenine · open the ingredient record
• Publication PMID 30166108 Research model: Animal Experiment
  Dang-Gui-Liu-Huang Tang a traditional herbal formula, ameliorates imiquimod-induced psoriasis-like skin inflammation in mice by inhibiting IL-22 production
  Condition or outcome area: psoriasis-like inflammation; psoriasis; epidermal hyperplasia; inflammatory skin disease; psoriatic lesions; imiquimod
  Phytomedicine · 2018 · Subject: Dang Gui Liu Huang Tang; 当归六黄汤; Danggui Liuhuang Decoction; Dang Gui Liu Huang Decoction · open the formula record · DOI 10.1016/j.phymed.2018.04.051
• Publication PMID 35563819 Research model: Cell Experiment
  Alpha-Linolenic Acid Modulates T Cell Incorporation in a 3D Tissue-Engineered Psoriatic Skin Model
  Condition or outcome area: psoriasis; autoimmune skin disease; psoriatic; Psoriasis
  Cells · 2022 · Subject: (z,z,z)-9,12,15-octadecatrienoic acid; Linolenic Acid; linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid · open the ingredient record · DOI 10.3390/cells11091513
• Publication PMID 34381369 Research model: Animal Experiment
  L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines
  Condition or outcome area: psoriasis; skin inflammation; skin inflammatory disease; Psoriasis
  Front Pharmacol · 2021 · Subject: Theanine; L-Theanine; 3081-61-6; N-Ethyl-L-glutamine; Theanin; Suntheanine; (S)-2-Amino-5-(ethylamino)-5-oxopentanoic acid; N5-Ethyl-L-glutamine; CCRIS 7326; C7H14N2O3 · open the ingredient record · DOI 10.3389/fphar.2021.719842
• Publication PMID 35126161 Research model: Animal & Cell Experiment
  Sulforaphane Ameliorates the Severity of Psoriasis and SLE by Modulating Effector Cells and Reducing Oxidative Stress
  Condition or outcome area: inflammatory or autoimmune skin diseases; systemic lupus erythematosus; inflammatory and autoimmune diseases; psoriasis; acanthosis; proteinuria; lupus-
  Front Pharmacol · 2022 · Subject: Sulforathane; Sulforaphane; sulforaphane; 4478-93-7; DL-Sulforaphane; 1-Isothiocyanato-4-(methylsulfinyl)butane; D,L-Sulforaphane; Sulforafan; 1-isothiocyanato-4-methylsulfinylbutane; 1-Isothiocyanato-4-(methylsulfinyl)-butane · open the ingredient record · DOI 10.3389/fphar.2022.805508
• Publication PMID 34008239 Research model: Animal Experiment
  Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway
  Condition or outcome area: psoriasis; psoriasis-like mouse dermatitis; psoriasis-like skin inflammation
  Phytother Res · 2021 · Subject: Rosmarinic acid; 20283-92-5; Rosemary acid; Labiatenic acid; Rosmarinicacid; Labiatic acid; (R)-rosmarinic acid; trans-Rosmarinic acid; Rosemaric acid; Rosmarinate · open the ingredient record · DOI 10.1002/ptr.7155
• Publication PMID 33986690 Research model: Cell Experiment
  Biotechnologically Produced Lavandula angustifolia Mill. Extract Rich in Rosmarinic Acid Resolves Psoriasis-Related Inflammation Through Janus Kinase/Signal Transducer and Activator of Transcription Signaling
  Condition or outcome area: psoriasis; Psoriasis; psoriasis-associated inflammation
  Front Pharmacol · 2021 · Subject: Rosmarinic acid; 20283-92-5; Rosemary acid; Labiatenic acid; Rosmarinicacid; Labiatic acid; (R)-rosmarinic acid; trans-Rosmarinic acid; Rosemaric acid; Rosmarinate · open the ingredient record · DOI 10.3389/fphar.2021.680168
• Publication PMID 35153790 Research model: Animal & Cell Experiment
  Punicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion
  Condition or outcome area: inflammation; epidermal hyperplasia; tumor; psoriasis; chronic and inflammatory skin disorder; Psoriasis
  Front Pharmacol · 2022 · Subject: Punicalagin; HSDB 8106; DTXSID40894768; 3,4,5,16,17,18-Hexahydroxy-8,13-dioxo-11-(3,4,5,11,17,18,19,22,23,34,35-undecahydroxy-8,14,26,31-tetraoxo-9,13,25,32-tetraoxaheptacyclo[25.8.0.02,7.015,20.021,30.024,29.028,33]pentatriaconta-1(35),2,4,6,15,17,19,21,23,27,29,33-dodecaen-10-yl)-9,12-dioxatricyclo[12.4.0.02,7]octadeca-1(18),2,4,6,14,16-hexaene-10-carbaldehyde; D-Glucose, cyclic 4,6-(2,2'-(5,10-dihydro-2,3,7,8-tetrahydroxy-5,10-dioxo(1)benzopyrano(5,4,3-cde)(1)benzopyran-1,6-diyl)bis(3,4,5-tri · open the ingredient record · DOI 10.3389/fphar.2022.817526
• Publication PMID 31924750 Research model: Cell Experiment
  Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
  Condition or outcome area: psoriasis-like skin inflammation; splenomegaly; psoriasis; Psoriasis; autoimmune skin disease; epidermal hyperplasia; abnormal keratinocytes hyperproliferation
  Cell Death Dis · 2020 · Subject: Piplartine; Piperlongumine; 20069-09-4; UNII-SGD66V4SVJ; SGD66V4SVJ; (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one; CHEBI:8241; 2(1H)-Pyridinone, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-; MFCD00075706; 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one · open the ingredient record · DOI 10.1038/s41419-019-2212-y
• Publication PMID 33291656 Research model: Clinical & Cell Experiment
  Phorbol 12-Myristate 13-Acetate Induced Toxicity Study and the Role of Tangeretin in Abrogating HIF-1α-NF-κB Crosstalk In Vitro and In Vivo
  Condition or outcome area: intra-epidermal neutrophilic abscesses; psoriasis; tumor; epidermal hyperplasia; mitotic dysfunction; embryonic and larval deformities; cutaneous inflammation
  Int J Mol Sci · 2020 · Subject: Phorbol 12-myristate 13-acetate; 16561-29-8; phorbol-12-myristate-13-acetate; 12-O-Tetradecanoylphorbol-13-acetate; 12-O-Tetradecanoylphorbol 13-acetate; Tetradecanoylphorbol acetate; Phorbol ester; Factor A1; 12-Tetradecanoylphorbol 13-acetate; Phorbol myristate acetate · open the ingredient record · DOI 10.3390/ijms21239261
• Publication PMID 34929480 Research model: Animal & Cell Experiment
  Perillyl alcohol inhibits keratinocyte proliferation and attenuates imiquimod-induced psoriasis like skin-inflammation by modulating NF-κB and STAT3 signaling pathways
  Condition or outcome area: psoriatic like skin inflammation; chronic inflammatory and proliferative skin disease; epidermal hyperplasia; splenomegaly; imiquimod; skin lesions; psoriasis; acanthosis; psoriasis-like skin inflammation; Psoriasis; hyper-keratosis
  Int Immunopharmacol · 2021 · Subject: Perillyl alcohol; 536-59-4; Perilla alcohol; Perillol; Isocarveol; p-Mentha-1,8-dien-7-ol; Hydrocumin alcohol; 1-Cyclohexene-1-methanol, 4-(1-methylethenyl)-; Dihydrocuminyl alcohol; Iso-carveol · open the ingredient record · DOI 10.1016/j.intimp.2021.108436
• Publication PMID 35095512 Research model: Animal Experiment
  Paeonol Ameliorates Chronic Itch and Spinal Astrocytic Activation via CXCR3 in an Experimental Dry Skin Model in Mice
  Condition or outcome area: psoriasis; dry skin disease; atopic dermatitis; skin inflammation; chronic dermatitis
  Front Pharmacol · 2022 · Subject: Paeonol; 552-41-0; 2'-Hydroxy-4'-methoxyacetophenone; 1-(2-Hydroxy-4-methoxyphenyl)ethanone; Peonol; 2-Hydroxy-4-methoxyacetophenone; Ethanone, 1-(2-hydroxy-4-methoxyphenyl)-; 1-(2-hydroxy-4-methoxyphenyl)ethan-1-one; 4-O-Methylresacetophenone; Resacetophenone-4-methyl ether · open the ingredient record · DOI 10.3389/fphar.2021.805222
• Publication PMID 36466901 Research model: Animal & Cell Experiment
  Indirubin combined with umbilical cord mesenchymal stem cells to relieve psoriasis-like skin lesions in BALB/c mice
  Condition or outcome area: Psoriasis; dermis hyperplasia; skin lesions; psoriasis; psoriatic lesions; parakeratosis; keratinization
  Front Immunol · 2022 · Subject: Indirubin; 479-41-4; Indigo Red; Couroupitine B; 906748-38-7; Indigopurpurin; (Z)-[2,3'-biindolinylidene]-2',3-dione; 397242-72-7; (E)-[2,3'-biindolinylidene]-2',3-dione; Isoindirubin · open the ingredient record · DOI 10.3389/fimmu.2022.1033498
• Publication PMID 34025642 Research model: Animal & Cell Experiment
  Hyperforin Ameliorates Imiquimod-Induced Psoriasis-Like Murine Skin Inflammation by Modulating IL-17A-Producing γδ T Cells
  Condition or outcome area: stroke; psoriasis; depressive disorders; cutaneous skin lesions; chronic immune-mediated inflammatory skin disease; Psoriasis; imiquimod-induced splenomegaly; imiquimod
  Front Immunol · 2021 · Subject: Hyperforin; 11079-53-1; hiperforina; hyperforine; CHEBI:5834; RM741E34FP; CHEMBL1237210; (1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione; (+)-Hyperforin; (1R,5S,6R,7S)-4-hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione · open the ingredient record · DOI 10.3389/fimmu.2021.635076
• Publication PMID 31790685 Research model: Animal Experiment
  The potential of Diosgenin in treating psoriasis: Studies from HaCaT keratinocytes and imiquimod-induced murine model
  Condition or outcome area: psoriatic lesions; Psoriasis; keratinocyte hyperproliferation; cutaneous disease
  Life Sci · 2020 · Subject: Diosgenin; 512-04-9; Nitogenin; (3beta,25R)-spirost-5-en-3-ol; Diosgenine; UNII-K49P2K8WLX; K49P2K8WLX; (20R,25R)-Spirost-5-en-3beta-ol; CCRIS 6803; CHEBI:4629 · open the ingredient record · DOI 10.1016/j.lfs.2019.117115
• Publication PMID 33081840 Research model: Cell Experiment
  Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice
  Condition or outcome area: psoriasis; erythema; chronic inflammatory skin disease; Psoriasis; skin lesion
  Biol Res · 2020 · Subject: Daphnetin; 486-35-1; 7,8-Dihydroxycoumarin; Daphnetol; 7,8-Dihydroxy-2H-chromen-2-one; 7,8-Dihydroxy-2H-1-benzopyran-2-one; 7,8-dihydroxychromen-2-one; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-; 7,8-DIHYDROXY-2H-BENZOPYRAN-2-ONE; TCMDC-125839 · open the ingredient record · DOI 10.1186/s40659-020-00316-0
• Publication PMID 36120325 Research model: Clinical & Animal Experiment
  Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms
  Condition or outcome area: psoriatic dermatitis; tumor; chronic and immune-mediated inflammatory skin disease; psoriasis; Psoriasis
  Front Pharmacol · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3389/fphar.2022.903160
• Publication PMID 35056961 Research model: Cell Experiment
  Oxyresveratrol Inhibits TNF-α-Stimulated Cell Proliferation in Human Immortalized Keratinocytes (HaCaT) by Suppressing AKT Activation
  Condition or outcome area: psoriasis; inflammatory disease; psoriatic; Psoriasis
  Pharmaceutics · 2021 · Subject: Cudranin; Oxyresveratrol; 29700-22-9; Hydroxyresveratrol; Tetrahydroxystilbene; (E)-4-(3,5-Dihydroxystyryl)benzene-1,3-diol; trans-oxyresveratrol; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol; 4721-07-7; 1,3-Benzenediol, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]- · open the ingredient record · DOI 10.3390/pharmaceutics14010063
• Publication PMID 34576119 Research model: Cell Experiment
  Disease-Dependent Antiapoptotic Effects of Cannabidiol for Keratinocytes Observed upon UV Irradiation
  Condition or outcome area: psoriasis; psoriatic; Psoriasis; chronic autoimmune-mediated skin disease; necrosis
  Int J Mol Sci · 2021 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record · DOI 10.3390/ijms22189956
• Publication PMID 36527884 Research model: Animal & Cell Experiment
  Kaempferol modulates IFN-γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions
  Condition or outcome area: Immune-mediated inflammation; skin lesions; psoriasis; psoriasis-like skin lesions; psoriatic
  Int Immunopharmacol · 2022 · Subject: Campherol; Kaempferol; kaempferol; 520-18-3; Kaempherol; Robigenin; Populnetin; Rhamnolutein; Trifolitin; Kempferol · open the ingredient record · DOI 10.1016/j.intimp.2022.109585
• Publication PMID 35023281 Research model: Animal Experiment
  Topical astilbin ameliorates imiquimod-induced psoriasis-like skin lesions in SKH-1 mice via suppression dendritic cell-Th17 inflammation axis
  Condition or outcome area: autoimmune diseases; imiquimod; skin lesions; psoriasis; inflammatory skin disorder; psoriatic
  J Cell Mol Med · 2022 · Subject: Astilbin; 29838-67-3; Taxifolin 3-O-rhamnoside; Isoastilbin; Dihydroquercitrin; CHEBI:38200; Dihydroquercetin 3-rhamnoside; (2R-cis)-isomer of astilbin; dihydroquercetin-3-O-alpha-LRhap; DTXSID501019948 · open the ingredient record · DOI 10.1111/jcmm.17184
• Publication PMID 34603793 Research model: Cell Experiment
  Identification of phosphodiesterase-4 as the therapeutic target of arctigenin in alleviating psoriatic skin inflammation
  Condition or outcome area: psoriasis; Imiquimod-induced murine psoriasis; imiquimod-induced murine psoriasis
  J Adv Res · 2021 · Subject: Arctigenin; (-)-Arctigenin; 7770-78-7; (+/-)-Arctigenin; Arctigenin, (+/-)-; UNII-U76MR9VS6M; U76MR9VS6M; Arctigenin, trans-((+/-)-; C21H24O6; (3R,4R)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)dihydrofuran-2(3H)-one · open the ingredient record · DOI 10.1016/j.jare.2021.02.006
• Publication PMID 32610574 Research model: Cell Experiment
  Effects of Apigenin on RBL-2H3, RAW264.7, and HaCaT Cells: Anti-Allergic, Anti-Inflammatory, and Skin-Protective Activities
  Condition or outcome area: immune-related diseases; psoriasis; tumor; atopic dermatitis; chronic disease; skin disease; acne
  Int J Mol Sci · 2020 · Subject: Apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Versulin; Apigenol; Chamomile; 4',5,7-Trihydroxyflavone; Spigenin; Apigenine; C.I. Natural Yellow 1 · open the ingredient record · DOI 10.3390/ijms21134620
• Publication PMID 33107318 Research model: Animal Experiment
  Imperatorin Alleviates Psoriasiform Dermatitis by Blocking Neutrophil Respiratory Burst, Adhesion, and Chemotaxis Through Selective Phosphodiesterase 4 Inhibition
  Condition or outcome area: psoriasis; keratinocyte hyperproliferation; epidermal thickening; skin desquamation; psoriasiform dermatitis; neutrophilic psoriasis
  Antioxid Redox Signal · 2021 · Subject: Ammidin; Pentosalen; IMPERATORIN; 482-44-0; Marmelosin; 8-Isoamylenoxypsoralen; 8-Isopentenyloxypsoralene; Marmelide; NSC 402949; 9-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one · open the ingredient record · DOI 10.1089/ars.2019.7835
• Publication PMID 36355777 Research model: Animal Experiment
  Allicin ameliorates imiquimod-induced psoriasis-like skin inflammation via disturbing the interaction of keratinocytes with IL-17A
  Condition or outcome area: skin allergy; inflammatory skin disease; psoriasis-; psoriasis; dermatitis; Psoriasis
  Br J Pharmacol · 2022 · Subject: Allicin; 539-86-6; Diallyl thiosulfinate; S-allyl prop-2-ene-1-sulfinothioate; Diallyldisulfid-S-oxid; Thio-2-propene-1-sulfinic acid S-allyl ester; Allylthiosulphinic acid allyl ester; 2-Propene-1-sulfinothioic acid, S-2-propenyl ester; DADSO; S-Allyl acrylo-1-sulphinothioate · open the ingredient record · DOI 10.1111/bph.15983
• Publication PMID 33990689 Research model: Animal & Cell Experiment
  2'-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice
  Condition or outcome area: prostate cancer; STAT3-mediated skin disorders; psoriasis; inflammation; epidermal thickening; keratinocyte hyperproliferation; dermatitis; chronic autoimmune skin disease
  Exp Mol Med · 2021 · Subject: 2'-hydroxycinnamaldehyde; 3-(2-Hydroxyphenyl)prop-2-enal; 3-(2-hydroxyphenyl)prop-2-enal; o-Hydroxy-trans-cinnamaldehyde; 2-Propenal, 3-(2-hydroxyphenyl)-, (E)-; (2E)-3-(2-Hydroxyphenyl)-2-propenal; DTXSID301313734; AKOS030230060 · open the ingredient record · DOI 10.1038/s12276-021-00620-z
• Publication PMID 35153762 Research model: Animal Experiment
  P. granatum Peel Polysaccharides Ameliorate Imiquimod-Induced Psoriasis-Like Dermatitis in Mice via Suppression of NF-κB and STAT3 Pathways
  Condition or outcome area: psoriasis; tumor; chronic and refractory inflammatory and autoimmune-mediated cutaneous disease; Psoriasis
  Front Pharmacol · 2022 · Subject: Shi Liu; 石榴; Pomegranate Fruit; Fructus Punixae Granati · open the herb record · DOI 10.3389/fphar.2021.806844
• Publication PMID 34955833 Research model: Animal & Cell Experiment
  Astragalus mongholicus Bunge Water Extract Exhibits Anti-inflammatory Effects in Human Neutrophils and Alleviates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice
  Condition or outcome area: psoriasis-like skin inflammation; inflammatory diseases; psoriasis; neutrophilic inflammation; anti-psoriasis; skin inflammation; oxidative stress-related inflammatory diseases; psoriasis-
  Front Pharmacol · 2021 · Subject: Meng Gu Huang Qi; 蒙古黄芪; Mongolian Milkvetch; Astragalus Mongholicus · open the herb record · DOI 10.3389/fphar.2021.762829
• Publication PMID 34634367 Research model: Animal Experiment
  Aqueous extract of Solanum nigrum attenuates Angiotensin-II induced cardiac hypertrophy and improves cardiac function by repressing protein kinase C-ζ to restore HSF2 deSUMOlyation and Mel-18-IGF-IIR signaling suppression
  Condition or outcome area: diarrhoea; hydrophobia; fever; cardiac hypertrophy; chronic skin ailments; psoriasis; heart failure; ringworm; eye diseases; hypertension; inflammatory conditions; liver disorders
  J Ethnopharmacol · 2021 · Subject: Long Kui; 龙葵; Solanum Nigrum Linn.; Solani Nigri Herba · open the herb record · DOI 10.1016/j.jep.2021.114728
• Publication PMID 36421490 Research model: Cell Experiment
  Antioxidant, Anti-Inflammation and Antiaging Activities of Artocarpus altilis Methanolic Extract on Urban Particulate Matter-Induced HaCaT Keratinocytes Damage
  Condition or outcome area: skin diseases; atopic dermatitis; eczema; tumor; psoriasis
  Antioxidants (Basel) · 2022 · Subject: Mian Bao Shu; 面包树; Fleshy Artocarpus; Artocarpus Communis · open the herb record · DOI 10.3390/antiox11112304
• Publication PMID 31540162 Research model: Cell Experiment
  Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models
  Cells · 2019 · Subject: Fisetin; 528-48-3; 5-Desoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 3,3',4',7-Tetrahydroxyflavone; Fustel; Viset; 3,7,3',4'-Tetrahydroxyflavone; Fisetholz; Superfustel · open the ingredient record · DOI 10.3390/cells8091089